| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | -0.065 | 0.04 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.066 | 0.04 |
| mRNA | GDC-0941 | FIMM | pan-cancer | AAC | -0.36 | 0.04 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.04 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | -0.06 | 0.05 |
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | -0.074 | 0.05 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.05 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | -0.061 | 0.05 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.05 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | -0.062 | 0.05 |